Regeneron Pharmaceuticals delivered one of the standout results of the earnings season on Friday, reporting that quarterly revenue jumped 36 percent to $5.1 billion. The biotech’s performance, powered by its blockbuster treatments Dupixent and Eylea HD, helped healthcare shares outperform on a day when technology stocks were under heavy pressure. More earnings coverage is in our business news section.
Regeneron’s Blockbuster Drugs Do the Heavy Lifting
Regeneron’s growth continues to rest on two franchises. Dupixent, the anti-inflammatory treatment developed with Sanofi, keeps expanding into new conditions and patient groups, while Eylea HD, the high-dose version of its eye treatment, has been winning patients from the original formulation and rival products.
Adjusted earnings came in at $20.07 a share, comfortably ahead of expectations, and the shares rose strongly in early trading. Investors have rewarded the company for executing a transition many doubted it could manage — replacing revenue from an ageing flagship product with a higher-dose successor without losing the market to competitors.
Healthcare’s Defensive Appeal
Regeneron was not the only drugmaker to please the market. AbbVie raised its full-year adjusted earnings outlook after reporting revenue of $17.4 billion, up more than 10 percent, while AstraZeneca and Sanofi also gained following their results. The pattern made healthcare the week’s best-performing sector even as the broader market wobbled.
As earnings season reporting observes, investors have been rotating towards companies whose earnings do not depend on the artificial intelligence spending cycle. Drugmakers, with their patent-protected products and steady demand, fit that description neatly — at least until their own patent cliffs come into view.
The Pipeline Question
For Regeneron, the debate now shifts to durability: how long Dupixent can keep growing, and whether the company’s pipeline in cancer, gene therapy and rare diseases can produce the next wave of products. The company has been investing heavily in research, including genetic medicines, precisely to answer that question before the market asks it more sharply.
With cash generation strong and the shares re-rated after the results, management has room to keep investing. In an earnings season that punished hype, Regeneron’s quarter was a reminder of the market’s appetite for growth that is already visible in the numbers.
Regeneron’s 36 percent revenue jump made it a rare bright spot in a turbulent week for equities. As investors sort winners from casualties this earnings season, dependable growth — wherever it is found — is commanding a premium.
